The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Androgen Deprivation Therapy for Prostate Cancer
Abstract
CONTEXT: Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in US men. Androgen deprivation therapy (ADT), specifically surgical or medical castration, is the first line of treatment against advanced prostate cancer and is also used as an adjuvant to local treatment of high-risk disease. OBJECTIVE: To review systematically the evidence on the risks and benefits of ADT for prostate cancer as well as clinical management of its adverse effects. EVIDENCE ACQUISITION: We performed MEDLINE searches of English-language literature (1966 to March 2005) using the terms androgen deprivation therapy, hormone treatment, and prostate cancer. We reviewed bibliographies of literature to extract other relevant articles. Studies were selected based on clinical pertinence, with an emphasis on controlled study design. EVIDENCE SYNTHESIS: Androgen deprivation therapy is effective for palliation in many patients with advanced prostate cancer and improves outcomes for high-risk patients treated with radiation therapy for localized disease. Although patients with increasing prostate-specific antigen levels after local treatment without metastatic disease frequently undergo ADT, the benefits of this strategy are not clear. Adverse effects of ADT include decreased libido, impotence, hot flashes, osteopenia with increased fracture risk, metabolic alterations, and changes in cognition and mood. CONCLUSIONS: Androgen deprivation therapy has clear roles in the management of advanced prostate cancer and high-risk localized disease. The benefits of ADT in other settings need to be weighed carefully against substantial risks and adverse effects on quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
HUGGINS, C. (1941) · Archives of Surgery · doi:10.1001/archsurg.1941.01210140043004 · Cited by 1,499
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
Cited by
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61226-9 · Cited by 797
Galvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., & Newton, R. U. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2488 · Cited by 657
Stahlhut, R. W., van Wijngaarden, E., Dye, T. D., Cook, S., & Swan, S. H. (2007) · Environmental Health Perspectives · doi:10.1289/ehp.9882 · Cited by 646
Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975
La Vecchia, C., Bosetti, C., Lucchini, F., Bertuccio, P., Negri, E., Boyle, P., & Levi, F. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp530 · Cited by 559
Weineisen, M., Schottelius, M., Simecek, J., Baum, R. P., Yildiz, A., Beykan, S., Kulkarni, H. R., Lassmann, M., Klette, I., Eiber, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158550 · Cited by 532
Insulin sensitivity during combined androgen blockade for prostate cancer
Smith, M. R., Lee, H., & Nathan, D. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2507 · Cited by 493
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Shore, N. D., Saad, F., Cookson, M. S., George, D. J., Saltzstein, D. R., Tutrone, R., Akaza, H., Bossi, A., van Veenhuyzen, D. F., Selby, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004325 · Cited by 444
Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate Cancer
Greenspan, S. L., Coates, P., Sereika, S. M., Nelson, J. B., Trump, D. L., & Resnick, N. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0183 · Cited by 411
Androgen Signaling in Prostate Cancer
Dai, C., Heemers, H., & Sharifi, N. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030452 · Cited by 406
Self-citationCancer, Physical Activity, and Exercise
Brown, J. C., Winters‐Stone, K., Lee, A., & Schmitz, K. H. (2012) · Comprehensive Physiology · doi:10.1002/cphy.c120005 · Cited by 346
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
Chang, K.-H., Li, R., Papari-Zareei, M., Watumull, L., Zhao, Y. D., Auchus, R. J., & Sharifi, N. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107898108 · Cited by 346
Self-citationImpact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes
Alibhai, S. M. H., Duong-Hua, M., Sutradhar, R., Fleshner, N. E., Warde, P., Cheung, A. M., & Paszat, L. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0923 · Cited by 334
De Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
Androgens and estrogens in benign prostatic hyperplasia: Past, present and future
Nicholson, T. M., & Ricke, W. A. (2011) · Differentiation · doi:10.1016/j.diff.2011.04.006 · Cited by 331
Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancer
Taylor, L. G., Canfield, S. E., & Du, X. L. (2009) · Cancer · doi:10.1002/cncr.24283 · Cited by 324
Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men
Lunenfeld, B., Mskhalaya, G., Zitzmann, M., Arver, S., Kalinchenko, S., Tishova, Y., & Morgentaler, A. (2015) · The Aging Male · doi:10.3109/13685538.2015.1004049 · Cited by 312
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Chang, K.-H., Li, R., Kuri, B., Lotan, Y., Roehrborn, C. G., Liu, J., Vessella, R., Nelson, P. S., Kapur, P., Guo, X., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.029 · Cited by 312
Self-citationGrün, F., & Blumberg, B. (2007) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-007-9049-x · Cited by 305
Resistance Training and Reduction of Treatment Side Effects in Prostate Cancer Patients
GALVÃO, D. A., NOSAKA, K., TAAFFE, D. R., SPRY, N., KRISTJANSON, L. J., MCGUIGAN, M. R., SUZUKI, K., YAMAYA, K., & NEWTON, R. U. (2006) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000233803.48691.8b · Cited by 297
Long Noncoding RNAs in Cancer: From Function to Translation
Sahu, A., Singhal, U., & Chinnaiyan, A. M. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.08.010 · Cited by 260
Storbeck, K.-H., Bloem, L. M., Africander, D., Schloms, L., Swart, P., & Swart, A. C. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.07.006 · Cited by 198
Management of Complications of Prostate Cancer Treatment
Michaelson, M. D., Cotter, S. E., Gargollo, P. C., Zietman, A. L., Dahl, D. M., & Smith, M. R. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2008.0002 · Cited by 196
Secondary Hormonal Therapy for Advanced Prostate Cancer
Lam, J. S., Leppert, J. T., Vemulapalli, S. N., Shvarts, O., & Belldegrun, A. S. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)00034-0 · Cited by 153
A new dawn for androgens: novel lessons from 11-oxygenated C19 steroids
Pretorius, E., Arlt, W., & Storbeck, K.-H. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.08.014 · Cited by 142
Steroid biosynthesis and prostate cancer
Sharifi, N., & Auchus, R. J. (2012) · Steroids · doi:10.1016/j.steroids.2012.03.015 · Cited by 116
Self-citationMcMillan, E. M., & Newhouse, I. J. (2011) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h11-082 · Cited by 120
Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases
Goyal, J., & Antonarakis, E. S. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.04.001 · Cited by 94
Effectiveness of Primary Androgen-Deprivation Therapy for Clinically Localized Prostate Cancer
Potosky, A. L., Haque, R., Cassidy-Bushrow, A. E., Ulcickas Yood, M., Jiang, M., Tsai, H.-T., Luta, G., Keating, N. L., Smith, M. R., & Van Den Eeden, S. K. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.5782 · Cited by 75
Koncarevic, A., Cornwall-Brady, M., Pullen, A., Davies, M., Sako, D., Liu, J., Kumar, R., Tomkinson, K., Baker, T., Umiker, B., et al. (2010) · Endocrinology · doi:10.1210/en.2010-0134 · Cited by 71
Management of side effects of androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.004 · Cited by 69
Hematological changes during androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.102 · Cited by 62
Gauthier-Landry, L., Bélanger, A., & Barbier, O. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.05.009 · Cited by 62
Chipperfield, K., Fletcher, J., Millar, J., Brooker, J., Smith, R., Frydenberg, M., & Burney, S. (2013) · Psycho-Oncology · doi:10.1002/pon.3269 · Cited by 56
The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer
Sharifi, N. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31823874a4 · Cited by 52
Self-citationEthical and medical considerations of androgen deprivation treatment of sex offenders
Gooren, L. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1540 · Cited by 39
Napora, J. K., Short, R. G., Muller, D. C., Carlson, O. D., Odetunde, J. O., Xu, X., Carducci, M., Travison, T. G., Maggio, M., Egan, J. M., et al. (2011) · Journal of Andrology · doi:10.2164/jandrol.110.010983 · Cited by 35
Schofield, P., Gough, K., Lotfi-Jam, K., Bergin, R., Ugalde, A., Dudgeon, P., Crellin, W., Schubach, K., Foroudi, F., Tai, K. H., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2687-1 · Cited by 30
Nrf2 sensitizes prostate cancer cells to radiation via decreasing basal ROS levels
Liu, M., Yao, X., Li, W., Geng, J., Yan, Y., Che, J., Xu, Y., & Zheng, J. (2015) · BioFactors · doi:10.1002/biof.1200 · Cited by 27
Acetylation: a new target for protein degradation in cancer
Crawford, C. E. W., & Burslem, G. M. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2025.01.013 · Cited by 20
Metadata
- Authors
- Sharifi, N.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-07-13
- Volume
- 294
- Issue
- 2
- Pages
- 238
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2161282696
- Cited by
- 1,083
- References
- 54
- FWCI
- 35.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.